D. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)
D. Boral Capital reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $9.00 target price on the stock. A number of other analysts have also recently commented on the stock. JMP Securities initiated coverage on shares […]
D. Boral Capital reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $9.00 target price on the stock. A number of other analysts have also recently commented on the stock. JMP Securities initiated coverage on shares […]
